CURRICULUM VITAE
OF
ALISON M. BENDELE, D.V.M., PH.D.
___________________________________________________________
Bolder BioPATH Inc.
5541 Central Ave.
Suite 160
Boulder, CO 80309
303 633-5400
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
Education
B.Sc.
Biomedical Science
Texas A&M University
College Station, Texas
1974
D.V.M.
Texas A&M University
College Station, Texas
1979
Ph.D.
Veterinary Pathology
Purdue University
Lafayette, Indiana
1984
Diplomate
American College of
Veterinary Pathologists
1985
Licensed
Veterinarian
Indiana, Texas
Employment History
Glass Animal Hospital
Indianapolis, Indiana
Small Animal Practitioner
1979-1980
Veterinary Pathology
Purdue University
Graduate Research and Teaching Assistant
1980-1984
Lilly Research Laboratories
A Division of Eli Lilly and Company
Indianapolis, Indiana
Senior Pathologist
1984-1990
Lilly Research Laboratories
1990-1993
Indianapolis, Indiana
Senior Research Pathologist/Group Leader Inflammation Research
Synergen
Boulder, Colorado
Veterinary Pathologist
1993-1994
Amgen Boulder Inc.
Boulder, Colorado
Lab Head Pharmacology
1995-1997
Amgen Boulder Inc.
Boulder, Colorado
Director Preclinical Research and Development
1997-1998
Bolder BioPATH Inc.
Boulder, CO
1998-present
Page 2
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
Professional Experience
Board Certified Veterinary Pathologist
30+ years experience in the pharmaceutical industry
8 years Eli Lilly and Co. (Indianapolis, IN)
2 years Synergen
5 years Amgen.
16+ years Bolder BioPATH
Experience in Toxicology at Eli Lilly and Co.
Study Director and/or Study Pathologist on GLP studies of a wide variety of
pharmaceutical and agricultural compounds. At the time of my resignation from Lilly, I was the
Toxicology Project Leader on a compound that was in Phase II clinical trials. In that capacity, I
was responsible for insuring that the appropriate toxicology studies were completed for worldwide registration. In addition, I was project pathologist on numerous other compounds.
Discovery/Development Research-Lilly, Synergen, Amgen
Primary interests are in rheumatoid and osteoarthritis(OA) research and the use of
animal models to investigate pathogenesis and possible points of therapeutic intervention.
In 1988 and 1989 my lab (at Lilly) discovered spontaneous OA in the knee joints of
guinea pigs. Subsequently our studies were directed towards manipulation of this naturallyoccurring disease in an effort to determine factors important in the pathogenesis.
In addition to having experience with OA models, I have also worked with most of the
traditional inflammation models (arthritis and others) and I have a respectable number of
publications in that area.
While at Lilly, I was Chairman of the Chronic Inflammation Research Group and later, a
member of the Skeletal Diseases Strategy Group. My responsibilities to that group included
pathology support for the discovery aspects of that project as well as design and implementation
of all toxicology studies on compounds derived from those efforts.
Research at Synergen was primarily in the area of neurotrophic factors for Parkinson's
disease (GDNF) and in restenosis. I have extensive experience in administering proteins directly
into the neuropil or lateral ventricles of the brain by both bolus and continuous infusion (tethered
and Alzet pump) methodologies and then evaluating the brains histologically for toxic effects as
well as distribution and transport of protein by immunohistochemistry. In the restenosis area, we
evaluated potential efficacy of protein inhibitors of various cytokines and growth factors in the rat
carotid angioplasty model. My laboratory was also responsible for studies on the pathogenesis of
interleukin-1 receptor antagonist induced skin reactions in humans dosed subcutaneously. As the
only pathologist at Synergen, I was responsible for the histopathologic evaluation of animal
tissues from in house pilot toxicology and various other studies for all proteins.
Amgen research activities include managing pharmacology, pathology and toxicology
group of approximately 20 people and insuring that appropriate preclinical pharmacology and pilot
toxicology studies were done to support advancing proteins and small molecules for treatment of
rheumatoid and osteoarthritis (plus other inflammatory diseases) to IND/NDA. Personal research
interests are in validating targets especially in the arthritis area.
Bolder BioPATH, Inc. is a contract pharmacology, toxicology and pathology company
specializing in the conduct of all aspects of arthritis and other inflammation models but also
performing pilot toxicology studies as well as histology/histopathology on GLP studies. Our goals
are to provide preclinical data to support advancing proteins and small molecules to IND/NDA
stage.
Page 3
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
Professional Societies
American College of Veterinary Pathologists
American Veterinary Medical Association
Society of Toxicology
Patents Issued or Filed
Bendele AM, Bryant HU, Schaus, J.M. Method of Treating Inflammation Using
Ergolines Analogues and BCD Tricyclic Ergoline Part-structure Analogues,
United States Patent No. 5,416,090. May 16, 1995.
Bendele AM.Combination Therapy Using an IL-1 Inhibitor for treating IL-1
Mediated Diseases. . United States Patent Application. US97/22720 Dec. 8,
1997.
Bendele AM.Senello, R., Edwards CK 3rd. Combination Therapy using a TNF
Binding Protein for Treating TNF-Mediated Diseases. United States Patent
Application. US97/22733 Dec. 8, 1997.
Editorial Board of Journals
Veterinary Pathology-1997, 1999, 2000
Ad hoc reviewer for numerous other journals
Listing of Publications
Arthritis/inflammation
Toxicology
Other
1. Bendele AM, Carlton WW, Nelson GE, Peterson RE, Grove MD.
Viridicatumtoxin mycotoxicosis in mice and rats. Toxicol Lett. 1984
Sep;22(3):287-91.
2. Bendele AM, Carlton WW, Krogh P, Lillehoj EB. Ochratoxin A
carcinogenesis in the (C57BL/6J X C3H)F1 mouse. J Natl Cancer Inst. 1985
Oct;75(4):733-42.
3. Bendele AM, Neal SB, Oberly TJ, Thompson CZ, Bewsey BJ, Hill LE,
Rexroat MA, Carlton WW, Probst GS. Evaluation of ochratoxin A for
mutagenicity in a battery of bacterial and mammalian cell assays. Food
Chem Toxicol. 1985 Oct;23(10):911-8.
4. Hoover DM, Bendele AM, Wightman WR, Thompson CZ, Hoyt JA.
Streptococcal enteropathy in infant rats. Lab Anim Sci. 1985 Dec;35(6):63541.
5. Bendele AM, Carlton WW. Incidence of obstructive uropathy in male
B6C3F1 mice on a 24-month carcinogenicity study and its apparent
prevention by ochratoxin A. Lab Anim Sci. 1986 Jun;36(3):282-5, 1986.
Page 4
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
6. Bendele AM, Carlton WW. Urologic Syndrome, Mouse. In: Jones TC, Mohr
U, Hunt RD, editors. Monographs on Pathology of Laboratory Animals,
Urinary System. New York: Springer Verlag; 1986. p. 369-75.
7. Bendele AM, White SL. Early histopathologic and ultrastructural alterations
in femorotibial joints of partial medial meniscectomized guinea pigs. Vet
Pathol. 1987 Sep;24(5):436-43.
8. Bendele AM. Progressive chronic osteoarthritis in femorotibial joints of
partial medial meniscectomized guinea pigs. Vet Pathol. 1987
Sep;24(5):444-8.
9. Selig WM, Bendele AM, Fleisch JH. Antigen-induced edema formation,
bronchoconstriction, and pulmonary vasospasm in the isolated perfused
guinea pig lung. Evidence for a secondary edemagenic response. Am Rev
Respir Dis. 1988 Sep; 138(3):552-9.
10. Hom J, Butler L, Riedl P, Bendele AM. The progression of the inflammation
in established collagen-induced arthritis can be altered by treatments with
immunological or pharmacological agents which inhibit T cell activities. Eur
J Immunol. 1988 Jun;18:881-8.
11. Bendele AM, Hulman JF. Spontaneous cartilage degeneration in guinea
pigs. Arthritis Rheum. 1988 Apr;31(4):561-5.
12. Hom J, Bendele AM, Carlson D. In vivo administration with IL-1 accelerates
the development of collagen-induced arthritis in mice. J Immunol. 1988 Aug
1;141(3):834-41.
13. Bendele AM, White SL, Hulman JF. Osteoarthrosis in guinea pigs:
histopathologic and scanning electron microscopic features. Lab Anim Sci
1989 Mar;39(2):115-21.
14. Bemis K, Bendele AM, Clemens J, Deldar A, Gidda J, Hamelink JL, Holland
D, Lamishaw B, McGrath J, Shannon H, et al. General pharmacology of
nizatidine in animals. Arzneimettelforschung. 1989 Feb;39(2):240-50.
15. Butler LD, Mohler KM, Layman NK, Carn RL, Riedl PE, Puckett LD,
Bendele AM. Interleukin-2 induced systemic toxicity: Induction of mediators
and immunopharmacologic intervention. Immunopharmacol Immunotoxicol.
1989;11(2-3):445-87.
16. Zuckerman SH, Bendele AM. Regulation of serum tumor necrosis factor in
glucocorticoid-sensitive and -resistant rodent endotoxin shock models. Infect
Immun 1989 Oct;57(10):3009-13.
17. Butler LD, Layman NK, Cain RL, Riedl PE, Mohler KM, Bobbitt JL, Belagajie
R, Sharp J, Bendele AM. Interleukin-1 induced pathophysiology: induction
of cytokines, development of histopathologic changes, and
immunopharmacologic intervention. Clin Immunol Immunopathol. 1989
Dec;53(3):400-21.
Page 5
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
18. Hom J, Cole H, Bendele AM. Interleukin- 1 enhances the development of
spontaneous arthritis in MRL/lpr mice. Clin Immunol Immunopathol. 1990
Apr;55(1):109-19.
19. Hoover DM, Bendele AM, Hoffman WP, Foxworthy PS, Eacho PI. Effects
of chronic treatment with the leukotriene D4 antagonist compound
LY171883 on Fischer 344 rats and rhesus monkeys. Fundam Appl Toxicol.
1990 Jan;14(1):123-30.
20. Chandrasekhar S, Harvey AK, Hrubey P and Bendele AM. Arthritis induced
by interleukin-1 is dependent on the site and frequency of intraarticular
injection. Clin Immunol Immunopathol. 1990 June;55(3):382-400.
21. Bendele AM, Hulman JF, Harvey AK, Hrubey PS, Chandrasekhar S.
Passive role of articular chondrocytes in quinolone-induced arthropathy in
guinea pigs. Toxicol Pathol. 1990;18(2):304-12.
22. Bendele AM, White SL, Hulman JF, Bean JS. Osteoarthritis: the guinea pig
as an animal model. Comp. Pathol. Bul. 1990;Vol XXII, No. 3: 3 and 6.
23. Lindstrom TD, Hanssen BR, Bendele AM. Effects of hepatic ischemiareperfusion injury on the hepatic mixed function oxidase system in rats.
Mol Pharmacol. 1990 Dec;38(6);829-35.
24. Bendele AM, Hoover DM, van Lier RB, Foxworthy PS, Eacho PI. Effects of
chronic treatment with the leukotriene D4-antagonist compound LY171883
on B6C3F1 mice. Fundam Appl Toxicol. 1990 Nov;15(4):676-82.
25. Bendele AM, Bean JS, Hulman JF. Passive role of articular chondrocytes
in the pathogenesis of acute meniscectomy-induced cartilage degeneration.
Vet Pathol. 1991 May;28(3):207-15.
26. Bendele AM, White SL, Hulman JF and Bean JS: Osteoarthritis, Model No.
379. In: Capen CC, Jones TC, Migaki G, editors. Handbook: Animal Models
of Human Disease. Fasc. 18. Washington, D.C.: Registry of Comparative
Pathology; 1991. p. 3-6.
27. Hom JT., Gliszcynski VL, Cole HW, Bendele AM. Interleukin 1 mediated
acceleration of type II collagen-induced arthritis: effects of anti-inflammatory
or anti-arthritic drugs. Agents Actions. 1991 Jul;33(3-4):300-9.
28. Bendele AM, Stengel PW, Silbaugh SA. Quantitation of bronchiolar
epithelial proliferation in A23187-exposed guinea pigs. Agents Actions.
1991 Sep;34(1-2):194-6.
29. Bendele AM, Hulman JF. Effects of body weight restriction on the
development and progression of spontaneous osteoarthritis in guinea pigs.
Arthritis Rheum. 1991 Sep;34(9):1180-4.
30. Hrubey PS, Harvey AK, Bendele AM, Chandrasekhar S. Effects of antiarthritic drugs on IL-1 induced inflammation in rats. Agents Actions. 1991
Sep;34(1-2):56-9.
Page 6
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
31. Benslay DN, Bendele AM. Development of a rapid screen for detecting and
differentiating immunomodulatory vs. anti-inflammatory compounds in rats.
Agents Actions. 1991 Sep;34(1-2): 254-6.
32. Bendele AM, Spaethe SM, Benslay DN, Bryant HU. Anti-inflammatory
activity of pergolide, a dopamine receptor agonist. J Pharmacol Exp Ther.
1991 Oct;259(1):169-75.
33. Williams P, Bendele A, Deldar A, McGrath J, Shelter T, Owen N. General
pharmacology of pergolide in animals. 2nd Communication: gastrointestinal,
renal and miscellaneous studies. Arzneimittelforschung. 1992
Jul;42(7):891-5.
34. Bendele AM, Benslay DN, Hom JT, Spaethe SM, Ruterbories KJ, Lindstrom
TD, Lee SJ, Naismith RW. Anti-inflammatory activity of BF 389, a Di-Tbutylphenol, in animal models of arthritis. J Pharmacol Exp Ther. 1992
Jan;260(1):300-5.
35. Bendele AM, Ruterbories KJ, Spaethe SM, Benslay DN, Lindstrom TD, Lee
SJ, Naismith RW. Correlation of anti-inflammatory activity with peak tissue
rather than peak plasma levels of BF 389. J Pharmacol Exp Ther. 1992
Mar;260(3):1194-8.
36. Wong WS, Bendele AM, Fleisch JH. Pharmacologic evaluation of A23187induced contractions of three distinct preparations of guinea pig lung
parenchymal strips. J Pharmacol Exp Ther. 1992 Feb;260(2):714-721.
37. Wong WS, Bloomquist SL, Bendele AM, Fleisch JH: Pharmacologic and
histologic examinations of regional differences of guinea pig lung: a role of
pleural surface smooth muscle in lung strip contraction. Br J Pharmacol.
1992 Mar;105(3):620-6.
38. Stengel PW, Bendele AM, Silbaugh SA. Inhaled A23187 produces a
preferential sensitization to substance P. Am Rev Respir Dis. 1993
Jan;147(1):196-201.
39. Hom JT, Estridge T, Cole H, Gliszczynski V, Bendele A. Effects of various
anti-T cell receptor antibodies on the development of type II collageninduced arthritis in mice. Immunol Invest. 1993 Jun;22(4):257-65.
40. Bendele AM, Hulman JF, White S, Brodhecker C, Bendele RA.
Hepatocellular proliferation in ibuprofen-treated mice. Toxicol Pathol.
1993;21(1):15-20.
41. Stengel PW, Bendele AM, Cockerham SL, Silbaugh SA. Sulfuric acid
induces airway hyperresponsiveness to substance P in the guinea pig.
Agents Actions. 1993;39 Spec No:C128-31.
42. Stengel PW, Bendele AM.and Silbaugh SA Salbutamol reduces A23187induced pulmonary inflammation and airway hyperresponsiveness to
substance P in the guinea pig. Pharmacol Communications 3:333-341,
1993.
Page 7
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
43. Roudebush RE, Magee DE, Benslay DN, Bendele AM, Bryant HU. Effects
of weight manipulation on bone loss due to ovariectomy and the protective
effects of estrogen in the rat. Calcif Tissue Int. 1993 Jul;53(1):61-4.
44. Stengel PW, Bendele AM, Cockerham SL, Silbaugh SA. Effect of
dexamethasone on A23187-induced airway responses in the guinea pig. Eur
J Pharmacol. 1994 Mar 3;253(3):253-259.
45. Bendele AM, Buenger DA, McGrath JP, Schmalz CA, Hanasono GK.
Chronic toxicity and pharmacokinetics of the 5-HT3 receptor antagonist
zatosetron (LY277359) in Fischer 344 rats. Fundam Appl Toxicol. 1994
May;22(4):494-504.
46. Chandrasekhar S, Panetta JA, Bendele AM. Inhibition of IL-1 induced
articular inflammation of rats by 4-aminothiazolidines, LY 221068 and LY
269415. Agents Actions. 1994 Aug; 42(1-2):67-70.
47. Shelter T, Bendele A, Buening M, Clemens J, Colbert W, Deldar A, Helton
D, McGrath J, Shannon H, Turk J, et al. General pharmacology of loracarbef
in animals. Arzneimittelforschung. 1993 Jan;43(1):60-70.
48. Hershenson MB, Kelleher MD, Naureckas ET, Abe MK, Rubinstein VJ,
Zimmerman A, Bendele AM, McNulty JA, Panettieri RA, Solway J.
Hyperoxia increases airway cell S-phase traversal in immature rats in vivo.
Am J Respir Cell Mol Biol. 1994 Sep;11(3):296-303.
49. Silbaugh SA, Stengel PW, Cockerham SL, Froelich LL, Bendele AM, Rippy
MK, Baker SR, Sofia MJ, Jackson WT. Aerosolized LTB4 produces delayed
onset increases in pulmonary gas trapping. Prostaglandins Leukot Essent
Fatty Acids. 1995 Feb;54(2):115-21.
50. Smale G, Bendele A, Horton WE Jr. Comparison of age-associated
degeneration of articular cartilage in Wistar and Fischer 344 rats. Lab Anim
Sci. 1995 Apr;45(2):191-4.
51. Bendele A, Means J, Shoufler J Schmalz C, Hanasono G, Symanowski J,
Adams E. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in
rhesus monkeys. Drug Chem Toxicol. 1995 Feb;18(1):61-82.
52. Martin D, Near SL, Bendele A, Russell DA. Inhibition of tumor necrosis
factor is protective against neurologic dysfunction after active immunization
of Lewis rats with myelin basic protein. Exp Neurol. 1995 Feb;131(2):221-8.
53. Bendele A, Colloton M, Vrkljan M, Morris J, Sabados K. Cutaneous mast
cell degranulation in rats receiving injections of recombinant human
interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible
clinical implications. J Lab Clin Med. 1995 Apr;125(4):493-500.
54. Bendele AM, Bendele RA, Hulman JF, Swann BP. Beneficial effects of
treatment with diacerhein in guinea pigs with osteoarthritis. Rev Prat. 1996
Mar 15;46(6 Spec No):S35-S39.
Page 8
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
55. Martin D, Relton JK, Miller G, Bendele A, Fisher N, Russell D. Cytokines as
therapeutic agents in neurological disorders. In: Rothwell N, editor.
Cytokines in the Nervous System. Texas:D.G. Landess Co.;1996. p. 163-77
56. Bendele AM, Bendele RA A chronic study of the efficacy and toxicity of
diacerein treatment of guinea pigs with osteoarthritis.Revue du Rhumatisme
1997.
57. Bendele AM. Urologic Syndrome, Mouse. In: Jones TC, Mohr U, Hunt RD,
editors. Monographs on Pathology of Laboratory Animals, Urinary System.
New York:Springer-Verlag;1997. p. 456-62.
58. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication:
renal tubular vacuolation in animals treated with polyethylene-glycolconjugated proteins. Toxicol Sci. 1997 Apr;42(2):152-7.
59. Relton JK, Neuberger TJ, Bendele AM, Martin D, Russell D.
Cytokines:Neurotoxicity and neuroprotection. In: Bar PR, Beal MF, editors.
Neuroprotection in CNS Diseases. New York:Dekker;1997. p. 225-41.
60. Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, van de Loo
FA, van den Berg WB. Prevention of murine collagen-induced arthritis in the
knee and ipsilateral paw by local expression of human interleukin-1 receptor
antagonist protein in the knee. Arthritis Rheum. 1997 May;40(5):893-900.
61. Campbell IK, Bendele A, Smith DA, Hamilton JA. Granulocyte-macrophage
colony stimulating factor exacerbates collagen-induced arthritis in mice. Ann
Rheum Dis. 1997 Jun;56(6):364-8.
62. Bendele A, McAbee T, Woodward M, Scherrer J, Collins D, Frazier J,
Chlipala E, McCabe D. Effects of interleukin-1 receptor antagonist in slowrelease hylan vehicle on rat type II collagen arthritis. Pharm Res. 1998
Oct;15(10):1557-61.
63. Bendele A, Sennello G, McAbee T, Frazier J, Chlipala E, Rich B. Effects of
Interleukin-1 receptor antagonist alone and in combination with
methotrexate in adjuvant arthritic rats. J Rheumatol. 1999 Jun;26(6):1225-9.
64. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D.
Efficacy of sustained blood levels of interleukin-1 receptor antagonist in
animal models of arthritis: Comparison of efficacy in animal models to
human clinical data. Arthritis Rheum. 1999 Mar;42(3):498-506.
65. Kuiper S, Joosten LA, Bendele AM, Edwards CK 3rd, Arntz OJ, Helsen MM,
Van de Loo FA, van den Berg WB. Different roles of tumor necrosis factor
alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine.
1998 Sep;10(9):690-702.
66. Hartsel SA, Chen C, Kennedy J, Bendele A, Wright C, Marshall W. Antiinflammatory activity of purine nucleoside analogues. Nucleosides
Nucleotides. 1997;16(7-9):1291-4.
Page 9
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
67. Silbaugh SA, Stengel PW, Cockerham SL, Froelich LL, Bendele AM,
Spaethe SM, Sofia MJ, Sawyer JS, Jackson WT. Pharmacologic actions of
the second generation leukotriene B4 receptor antagonist LY293111:in vivo
pulmonary studies. Naunyn Schmiedebergs Arch Pharmacol. 2000
Apr;361(4):397-404.
68. McComb J, Gould T, Chlipala E, Sennello G, Frazier J, Kieft G, Seely J,
Edwards CK 3rd, Bendele, A. Antiarthritic activity of soluble tumor necrosis
factor receptor type I forms in adjuvant arthritis: correlation of plasma levels
with efficacy. J Rheumatol. 1999 Jun;26(6):1347-51.
69. Bendele AM, McComb J, Gould T, Frazier J, Chlipala E, Seely J, Kieft G,
Edwards, CK 3rd. Effects of PEGylated soluble tumor necrosis factor
receptor type I (PEG sTNF-RI) alone and in combination with methotrexate
in adjuvant arthritic rats. Clin Exp Rheumatol. 199 Sep-Oct;17(5):553-60.
70. Bendele A McComb J, Gould T, McAbee T, Sennello G, Chlipala E, Guy M.
Animal models of arthritis: relevance to human disease. Toxicol Pathol.
1999 Jan-Feb;27(1):134-42.
71. Black LE, Bendele AM, Bendele RA, Zack PM, Hamilton M. Regulatory
decision strategy for entry of a novel biologic therapeutic with a clinically
unmonitorable toxicity into clinical trials: pre-IND meetings and a case
example. Toxicol Pathol. 1999 Jan-Feb;27(1):22-6.
72. Bendele AM, McComb J, Gould T, Frazier J, Chlipala ES, Seely J, Kieft G,
Wolf J, Edwards CK 3rd. Combination benefit of PEGylated soluble tumor
necrosis factor receptor type I (PEG sTNG-FI) and dexamethasone or
indomethacin in adjuvant arthritic rats. Inflamm Res. 1999 Aug;48(8):45360.
73. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Rich WJ, Edwards CK 3rd.
Combination benefit of treatment with thy cytokine inhibitors interleukin-1
receptor antagonist and PEGylated soluble tumor necrosis factor receptor
type I in animal models of rheumatoid arthritis. Arthritis Rheum. 2000
Dec;43(12):2648-59.
74. Davis MW, Feige U., Bendele AM, Martin SW, Edwards CK 3rd. Treatment
of rheumatoid arthritis with PEGylated recombinant human soluble tumour
necrosis factor receptor type I: a clinical update. Ann Rheum Dis. 2000
Nov;59 Suppl 1:i41-3.
75. Moreland LW, McCabe DP, Caldwell JR, Sach M, Weisman M, Henry G,
Seely JE, Martin SW, Yee CL, Bendele AM, et al. Phase I/II trial of
recombinant methionyl human tumor necrosis factor binding protein
PEGylated dimer in patients with active refractory rheumatoid arthritis. J
Rheumatol. 2000 Mar;27(3):601-9
76. Bendele AM. Animal models of osteoarthritis. J Musculoskelet Neuronal
Interact. 2001 Jun;1(4):363-76.
77. Bendele AM. Animal Models of rheumatoid arthritis. J Musculoskelet
Neuronal Interact. 2001 Jun;1(4):377-85.
Page 10
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
78. Janusz MJ, Bendele AM, Brown KK, Taiwo YO, Hsieh L, Heitmeyer SA.
Induction of osteoarthritis in the rat by surgical tear of the meniscus:
Inhibition of joint damage by a matrix metalloproteinase inhibitor.
Osteoarthritis Cartilage. 2002 Oct;10(10):785-91.
79. Ferguson VL, Simske SJ, Ayers RA, Bateman TA, Wang HT, Bendele A,
Rich B, Collins D, Scherrer J, Sennello R, Colagiovanni DB. Effect of MPC11 myeloma and MPC-11+IL-1 receptor antagonist on mouse bone
properties. Bone. 2002 Jan;30(1):109-16.
80. Bendele AM. Animal models of osteoarthritis in an era of molecular biology.
J Musculoskelet Neuronal Interact. 2002 Dec;2(6):501-3.
81. Bendele AM. Summary-Osteoarthritis Session: New Ideas in Cartilage
Biology. J Musculoskelet Neuronal Interact 2002;2(6): 524.
82. Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL,
Sylander ED, Rittman B, Bendele A, Sartor RB and Lichenstein HS. A novel
human fibroblast growth factor treats experimental intestinal inflammation.
Gastroenterology. 2002 Oct;123(4):1151-62.
83. Banda NK, Vondracek A, Kraus D, Dinarello CA, Kim SH, Bendele A,
Senaldi G, Arend WP. Mechanisms of inhibition of collagen-induced arthritis
by murine IL-18 binding protein. J Immunol. 2003 Feb 15;170(4):2100-5.
84. Trumble TN, Billinghurst RC, Bendele AM, McIlwraith CW. Evaluation of
changes in vertical ground reaction forces as indicators of meniscal damage
after transection of the cranial cruciate ligament in dogs. Am J Vet Res.
2005 Jan;66(1):156-63.
85. Cox GN, Smith DJ, Carlson SJ, Bendele AM, Chlipala EA, Doherty DH.
Enhanced circulating half-life and hematopoietic properties of a human
granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp
Hematol. 2004 May;32(5):441-9.
86. Edwards CK 3rd, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM,
Ellen Cosenza M, Feige U, Kohno T. Design of PEGylated soluble tumor
necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory
diseases. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1315-36.
87. Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS, Reardon B,
Ellsworth JL. Fibroblast growth factor-18 stimulates chondrogenesis and
cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthrits
Cartilage. 2005 Jul;13(7):623-31.
88. Mesri M, Smithson G, Ghatpande A, Chapoval A, Shenoy S, Boldog F,
Hackett C, Pena CE, Burgess C, Bendele A, et al. Inhibition of in vitro and
in vivo T cell responses by recombinant human Tim-1 extracellular domain
proteins. Int. immunol. 2006 Mar;18(3):473-84.
89. Dalby AB, Frank DN, St. Amand AL, Bendele AM, Pace NR. Cultureindependent analysis of indomethacin-induced alterations in the rat
Page 11
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
gastrointestinal microbiota. Appl Environ Microbiol. 2006 Oct;72(10):6707–
15.
90. Bendele AM. Animal Models. In: Bronner F, Farach-Carson MC. Bone and
Osteoarthritis (Topics in Bone Biology, Volume 4). London:SpringerVerlag;2007. p. 149-63.
91. Flannery CR, Zollner R, Corcoran C, Jones AR, Root A, Rivera-Bermudez
MA, Blanchet T, Gleghorn JP, Bonassar LJ, Bendele AM, et al. Prevention
of cartilage degeneration in a rat model of osteoarthritis by intraarticular
treatment with recombinant lubricin. Arthritis Rheum. 2009 Mar;60(3):8407.
92. Connor JR, LePage C, Swift BA, Yamashita D, Bendele AM, Maul D,
Kumar S. Protective effects of a cathepsin K inhibitor, SB-553484, in the
canine medial meniscectomy model of osteoarthritis. Osteoarthritis
Cartilage. 2009 Sep;17(9):1236-43.
93. Baragi VM, Becher G, Bendele AM, Biesinger R, Bluhm H, Boer J, Deng H,
Dodd R, Essers M, Feuerstein T, et al. A new class of potent matrix
metalloproteinase 13 inhibitors for potential treatment of osteoarthritis:
Evidence of histologic and clinical efficacy without musculoskeletal toxicity in
rat models. Arthritis Rheum. 2009 Jul;60(7): 2008-18.
94. Cecil DL, Appleton CT, Polewski MD, Mort JS, Schmidt AM, Bendele A,
Beier F, Terkeltaub R. The pattern recognition receptor CD36 is a
chondrocyte hypertrophy marker associated with suppression of catabolic
responses and promotion of repair responses to inflammatory stimuli. J
Immuno. 2009 Apr 15;182(8): 5024-31.
95. Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lower V,
O’Neill SP, Talor E, Rosenthal KS. CEL-2000: A therapeutic vaccine for
rheumatoid arthritis arrests disease development and alters serum
cytokine/chemokine patterns in the bovine collagen type II induced arthritis
in the DBA mouse model. Int Immunopharmacol. 2010 Apr;10(4): 412-21.
96. Gerwin N, Bendele A, Glasson S, Carlson CS. The OARSI histopathology
initiative – recommendations for histological assessments of osteoarthritis in
the rat. Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S24-34.
97. Kraus V, Huebner J, DeGroot J, Bendele A. The OARSI histopathology
initiative – recommendations for histological assessments of osteoarthritis in
the guinea pig. Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S35-52.
98. Settle S, Vickery L, Nemirovskiy O, Vidmar T, Bendele A, Messing D,
Ruminski P, Schnute M, Sunyer T. Cartilage degradation biomarkers
predict efficacy of a novel, highly selective matrix metalloproteinase 13
inhibitor in a dog model of osteoarthritis: confirmation by multivariate
analysis that modulation of type II collagen and aggrecan degradation
peptides parallels pathologic changes. Arthritis Rheum. 2010
Oct;62(10):3006-15.
Page 12
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
99. Shah V, Bendele A, Dines JS, Kestler HK, Hollinger JO, Chahine NO, Hee
CK. Dose-response effect of an intra-tendon application of recombinant
human platelet-derived growth factor-BB (rhPDGF-BB) in a rat Achilles
tendinopathy model. J Orthop Res. 2013 Mar;31(3):413-20.
100. Solchaga LA, Bendele A, Shah V, Snel LB, Kestler HK, Dines JS, Hee CK.
Comparison of the effect of intra-tendon applications of recombinant human
platelet-derived growth factor-BB, platelet-rich plasma, steroids in a rat
achilles tendon collagenase model. J Orthop Res. 2014 Jan;32(1):145-50.
101. Levine YA, Koopman FA, Faltys M, Caravaca A, Bendele A, Zitnik R,
Vervoordeldonk MJ, Tak PP. Neurostimulation of the cholinergic antiinflammatory pathway ameliorates disease in rat collagen-induced arthritis.
PLoS ONE. 2014 Aug 11;9(8):e104530.
102. Kyostio-Moore S, Piraino S, Berthelette P, Moran N, Serriello J, Bendele A,
Sookdeo C, Nambiar B, Ewing P, Armentano D, et al. Overexpression of
cystatin C in synovium does not reduce synovitis or cartilage degradation in
established osteoarthritis. Arthritis Res Ther. 2015 Jan 16;17(1):5.
103. Kumar A, Bendele AM, Blanks RC, Bodick N. Sustained efficacy of a single
intra-articular dose of FX006 in a rat model of repeated localized knee
arthritis. Osteoarthritis Cartilage. 2015 Jan;23(1): 151-60.
104. Rabinow B, Werling J, Bendele A, Gass J, Bogseth R, Balla K, Valaitis P,
Hutchcraft A, Graham S. Intra-articular (IA) ropivacaine microparticle
suspensions reduce pain, inflammation, cytokine, and substance p levels
significantly more than oral or IA celecoxib in a rat model of arthritis.
Inflammation. 2015 Feb;38(1):40-60.
Invited Lectures/Presentations
1. Bendele AM. Guinea pig models of osteoarthritis and cartilage degeneration.
Presented at The Kennedy Institute of Rheumatology. London, England.
June 1989.
2. Bendele AM. General responses of articular cartilage to injury. Presented to
the Great Lakes Pathologist Discussion Group, Spring meeting. Cincinnatti,
Ohio. March 1991.
3. Bendele AM.Animal models of arthritis and cartilage degeneration. Purdue
University, Toxicologic Pathology lecture series, July 1992.
4. Bendele AM.Cell proliferation models and toxicology. Purdue University,
Toxicologic Pathology lecture series, July 1992.
5. Bendele AM, Bendele RA, Hulman JF, Swann BP Beneficial effects of
diacerhein treatment on osteoarthritis in guinea pigs. Presented to the 2nd
OARS International Congress, Orlando, Fl, Dec. 1994.
6. Bendele AM.A chronic study of the efficacy and toxicity of diacerhein
treatment of guinea pigs with osteoarthritis. Presented to the 2nd International
Page 13
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
congress "Research and Therapeutics in Osteoarthritis: Interleukin 1
inhibitors", Nice, France. Feb. 1995.
7. Bendele AM.Challenges in demonstrating in vivo efficacy of matrix
metalloproteinase inhibitors as cartilage protectants. Inflammation Research
Association Meeting, New York, May, 1995.
8. Bendele AM.Guinea pig models of osteoarthritis and cartilage degeneration
for use in drug testing. IBC's Fifth International Conference on Arthritis, New
Orleans, Louisiana, Nov. 1995.
9. Bendele AM.General Responses of Articular Cartilage to Injury. Research
Seminar Series Colorado State University. Sept. 1996.
10. Bendele AM.Effects of IL-1ra in rheumatoid arthritis patients vs various
animal models of inflammatory arthritis. National Managed Health Care
Congress, Philadelphia, Oct. 1997.
11. Bendele AM.Role of Cytokines in Animal Models of Rheumatoid and
Osteoarthritis. American College of Veterinary Pathologists, Albuquerque,
Nov. 1997.
12. Bendele AM.Relevance of Animal Models of Rheumatoid and Osteoarthritis
to Human Clinical Disease. C.L. Davis Meeting, Hoffman LaRoche, Oct.
1997.
13. Bendele AM.IL-1ra: Comparative Efficacy in Rheumatoid Arthritis Patients vs.
Animal Models of Arthritis. 4th International Anti-inflammatory Drug Discovery
Summit. Miami Florida Feb. 1998.
14. Bendele AM.Preclinical Testing of Biotechnology Products in Preparation for
IND Submission. University of Colorado, Invited Guest Lecture. April, 1998.
15. Bendele AM.Animal Models of Arthritis Utilized in the Pharmaceutical
Industry-a Review for Toxicologic Pathologists. SOTP meeting, Vancouver,
B.C. June, 1998.
16. Lauren Black (FDA) Bendele A.M. A mockup of a pre-IND presentation and
followup in development of a Biologic Agent, SOTP meeting, Vancouver,
B.C. June, 1998.
17. Bendele AM, Animal Models of Rheumatoid and Osteoarthritis for Drug
Testing:Relevance to Human Disease. ASBMR, Toronto, Sept. 2000.
18. Bendele A.M. Animal Models of Osteoarthritis:Relevance to Human
Disease, Sun Valley Hard Tissue Workshop, Sun Valley Idaho, August 2002.
19. Bendele A.M. Lesions From Animal Models of Osteoarthritis. American
College of Rheumatology Meeting, Invited Lecture, Orlando, Fla., October
2003.
20. Bendele A.M. Diversity of Animal Models of Osteoarthritis. Cleveland Clinic
Cartilage Summit, Invited Lecture. Cleveland, Ohio, May 2005.
Page 14
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
21. Bendele A.M. Histopathological Criteria for Evaluating OA in Small Animals.
OARSI World Congress on OA. Ft Lauderdale, Dec 8, 2007.
Page 15
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
Abstracts, Presentations, Posters
1. Bendele AM, Carlton WW, Krogh P,Lillehoj EB. Ochratoxin A carcinogenesis
in the B6C3F1 mouse. Abstract and presentation at Congress of Animal
Research Workers. Chicago, Illinois. Nov. 1983.
2. Bendele AM. Canine Histoplasmosis. Presentation at summer meeting of
Midwest Association of Veterinary Pathologists. Marshall, Indiana. Aug.
1983.
3. Bendele AM. Granulomatous enteritis of rabbits. Presentation at summer
meeting of Midwest Association of Veterinary Pathologists. Nashville,
Indiana. Aug. 1984.
4. Hom J T., Harlan C, Bendele AM. IL1 treatments enhance the development
of Type II collagen-indujced arthritis in several different
mouse strains. Abstract, poster, presentation at Inflammation Research
Association meeting. White Haven, Pennsylvania. Oct. 1988.
5. Chandrasekhar S, Harvey AK, Hrubey PS, Zimmerman DJ, Bendele AM. IL1induced inflammatory response in rats: Effects of nonsteroidal antiinflammatory drugs. Abstract, poster, presentation at Inflammation Research
Association meeting. White Haven, Pennsylvania. Oct. 1988.
6. Bendele AM. Spontaneous osteoarthritis in Hartley albino guinea pigs:
Effects of dietary and surgical manipulations. Abstract and poster at
American College of Rheumatology meeting. Cincinnati, Ohio. June 1989.
7. Lindstrom TD, Bendele AM, Hanssen BR. Effects of ischemia-reperfusion
injury on hepatic drug metabolism. Abstract and poster for ASPET. Salt Lake
City, Utah. Aug. 1989.
8. Bendele AM, Hulman JF, Harvey AK, Hrubey PS, Chandrasekhar S.
Quinolone-induced arthropathy in guinea pigs. Abstract and presentation at
American College of Veterinary Pathologists meeting. Baltimore, Maryland.
Dec. 1989.
9. Bendele AM, Stengal PW, Silbaugh SA. Quantitation of broncheolar
epithelial proliferation in A23187 exposed guinea pigs. Abstract presented at
Inflammation Research Association meeting. Sept. 1990.
10. Benslay DN, Bendele AM. Development of a rapid screen for detecting and
differentiating immunomodulatory vs. anti-inflammatory compounds in rats.
Abstract presented at Inflammation Research Association meeting. Sept.
1990.
11. Hrubey PS, Harvey AK, Bendele AM, Chandrasekhar S. Effects of antiarthritic drugs on IL-1 induced inflammation in rats. Abstract presented at
Inflammation Research Association meeting. Sept. 1990.
12. Stengel PW, Bendele AM, Silbaugh SA. Inhaled A23187 induces airway
hyperresponsiveness to substance P. Abstract presented at ASPET.
Milwaukee, Wisconsin. August 1990.
Page 16
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
13. Carterson, B., Blankenship-Paris, T., Bendele A, Chandrasekhar S
Biochemical characterization of proteoglycans from guinea pig cartilage with
spontaneous osteoarthritis. Abstract presented at the 37th ORS meeting.
Anaheim, California. March 1991.
14. Wong WSF., Bloomquist SL, Bendele AM.and Fleisch JH Functional and
histological study of guinea pig lung parenchymal strips (LPS) isolated from
different regions of the lung. Abstract and poster presented at FASEB
meeting. Atlanta, Georgia. April 1991
15. Bendele AM, Benslay DN, Spaethe SM, Bryant HU Anti-inflammatory activity
of pergolide in rats. Abstract and poster presented at ASPET, San Diego,
California. August 1991.
16. Bryant HU, Roudebush RE, Bendele AM, Benslay DN, Cohen, I.R., Armour,
H.K. and Koppel, G.A. Anti-inflammatory activity of an ergoline, LY243062, in
the absence of immunosuppression. Abstract and poster presented at
ASPET, San Diego, California. August 1991.
17. Wong WSF, Bendele AM, Fleisch JH Lung pleural smooth muscle as the
main contributor to A23187- and ovalbumin (OA)-induced guinea pig lung
parenchymal strips (LPS) contraction. Abstract and poster presented at
ASPET, San Diego, California. August 1991.
18. Gossett, L.S., Grindey, G.B., Bendele AM, Shih, C. Synthesis and biological
evaluation of a series of 2,4-diamino-6-(2-Phenylethyl)pyrido[2,3-d]pyrimidine
derivatives. Abstract and poster presentd at the ACS meeting, New York,
N.Y., August 1991.
19. Stengel PW, Bendele AM.and Silbaugh SA Salbutamol reduces A23187induced pulmonary inflammation and airway hyperresponsiveness to
substance P in the guinea pig. Abstract and poster presented at ASPET, San
Diego, California. August 1991.
20. Slater, R., Caterson, B., Blankenship-Paris, T., Bendele A and
Chandrasekhar S Application of monoclonal antibodies against chondroitin
sulfate epitopes that detect biochemical markers of osteoarthritis. Abstract
and poster presented at the combined meeting of the Orthopedic Research
Societies of USA, Japan and Canada, Banff, Canada. October 1991.
21. Hershenson, M., Kelleher, M., Panettieri, R., Zimmerman A, Hernandez C,
Bendele A and Solway J Hyperoxia increases airway cell number and Sphase traversal in immature rats in vivo. Abstract and poster presented to the
American Thoracic Society Meeting, Miami, Fla., May 1992.
22. Silbaugh SA, Stengel PW, Cockerham SL, Froelich LL, Bendele AM, Baker,
S.B., W.T. Jackson. Aerosolized LTB4 produces delayed onset airway
obstruction. Abstract and poster presented to the American Thoracic Society
Meeting, Miami, Fla., May 1992.
Page 17
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
23. Roudebush RE, Magee DE, Bendele AM, Benslay DN, Bryant HU Effects of
various weight matching regimes on bone loss in an ovariectomized rat
model. Abstract and poster presented to the FASEB Meeting, 1992.
24. Bryant HU, Bendele AM, Magee DE, Cole HW. and Spaethe SM
Pharmacologic profile of estrogen-induced uterine eosinophilia in the
ovariectomized (OVX) rat. Abstract and poster presented to the ASPET
Meeting, Orlando, Fla., 1992.
25. Spaethe SM, Bendele AM, Hoge, P., Hulman JF, Bryant HU Estradiolinduced uterine eosinophilic inflammation in rats: Effect of dexamethasone,
methotrexate, cyclosporine or piroxicam. Abstract and poster presented to the
ASPET Meeting, Orlando, Fla., 1992.
26. Stengel PW, Bendele AM, Cockerham SL, Silbaugh SA Sulfuric acid induces
airway hyperresponsiveness to substance P in the guinea pig. Abstract and
poster presented to the Inflammation Research Association Meeting,
Whitehaven, PA, 1992.
27. Bendele AM, Hulman JF, White SL, Brodhecker C and Bendele RA
Hepatocellular proliferation in ibuprofen treated mice. Abstract and
presentation at Amer. College Vet. Pathol. meeting, San Diego, CA,
Nov.1992.
28. Kim, D.C., Ash, K.P., Bendele AM, Colloton ME., Reitz, B. and Bloedow,
D.C. Glomerular filtration and proximal tubular cell uptake of recombinant
human interleukin 1 receptor antagonist (rhIl-1ra) in the rat. Amer. Assoc.
Pharm. Sci. San Diego, CA. Nov. 1994.
29. Near S, Martin D, Bendele A, Russell D A potent tumor necrosis factor (TNF)
inhibitor attenuates the clinical signs of experimental allergic
encephalomyelitis (EAE). Neuroscience. Miami, Florida. Nov. 1994.
30. Shopp GM., Suniga MA., Bendele AM, Hall, W.C. and Saddler, A.J. The
immunogenicity of a human protein drug (tumor necrosis factor binding
protein; TNFbp) in animal toxicology studies. Society of Toxicology.
Baltimore, MD, 1995.
31. Colagiovanni, D.B., McCabe, J., Evans, R.J., Bendele AM.and Edwards CK
Recombinant human tumor necrosis factor-binding protein (TNF-BP) protects
mutant MRL-lpr/lpr mice against LPS-galactosamine induced lethality. CHIInflammatory Cytokine Antagonists, Boston, Mass., Nov. 1995.
32. Martin D, Fisher N, Near S, Russell D, Bendele A, Relton, J. Tumor necrosis
factor and Interleukin-1 inhibition attenuate the clinical sequellae of
experimental allergic encephalomyelitis in rats. Cytokines in the
brain:Neuropathological aspects. Saint-de-Luz-France, April 26, 1996.
33. Bendele AM.and Dockstader, K. Beneficial effects of Tumor necrosis factor
binding protein in indomethacin-induced small intestinal injury in rats. 6th
International TNF Congress, Rhodes, Hellas, May 1996.
Page 18
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
34. Evans, R.J., McCabe, J.G., Bendele AM.and Edwards CK Efficacy of TNFbp
in the streptococcal cell wall induced reactivation model of arthritis.
ASBMB/ASIP/AAI Joint Meeting.
35. Colagiovanni, D.B., McCabe, J., Evans, R., Bendele A, Edwards CK 3rd.
Tumor necrosis factor binding protein (TNF-bp) protects fas mutant MRLlpr/lpr mice against LPS or superantigen/D-galactosamine-induced lethality.
6th International TNF Congress, Rhodes, Hellas, May 1996.
36. Bendele AM.and Sennello GM. Beneficial effects of combination therapy with
human interleukin 1 receptor antagonist and methotrexate in adjuvant arthritic
rats. ACR, Orlando, October, 1996.
37. Van de loo, F.A., Bakker, A., Joosten, L., Bendele A and van den Berg WB
Gene transfer of human IL-1ra into the knee prevented collagen arthritis in
both knee and draining paw. ACR, Orlando, October, 1996.
38. Roubenoff, R., Edwards CK 3rd., Kehayias, J., Smith, D., Adab, L., Bendele
A, Frazier J and Dinerello, C. TNF-a and leptin in adjuvant
arthritis:implications for inflammatory cachexia. ACR, Orlando, October, 1996.
39. Hartsel SA,Chen C, Kennedy J, Bendele A, Wright C, Marshall WS. Antiinflammtory activity of purine nucleoside analogues. International Nucleoside
and Nucleotide Roundtable, Sept 15-19, 1996.
40. Pinkard, D., Franklin, R.B., Hamilton, M., Xu, D. and Bendele A
Simultaneous portal and systemic blood sample collection in mice for
pharmacokinetic studies. AALAS, Anaheim, CA, Nov. 1997.
41. Bendele AM, Sennello G, McAbee T, Frazier J, Chlipala E Effects of
interleukin-1 receptor antagonist alone and in combination with methotrexate
in adjuvant arthritic rats. American College of Rheumatology,
42. Washington D.C. Nov. 1997.
43. Bendele AM, Sennello G, McAbee T, Frazier J, Chlipala E and Parker,
V.Sustained blood levels of interleukin-1 receptor antagonist improve efficacy
in animal models of arthritis:comparison to human clinical data. American
College of Rheumatology, Washington D.C. Nov. 1997.
44. Collins, D.., McAbee T, Woodward M, Frazier J, Chlipala E and Bendele A
A slow release formulation of interleukin-1 receptor antagonist (IL-1ra)
exhibits improved in vivo activity. American College of Rheumatology,
Washington D.C. Nov. 1997.
45. Bendele AM, McComb J, Gould T, Chlipala E, Frazier J, Colagiovanni, D.,
Edwards CK 3rd. Comparative efficacy of sTNF-RI, a novel monomeric
recombinant soluble TNF type I receptor, to dimeric sTNF-RI and sTNF-RII
IgG1 Fc fusion proteins in animal models of rheumatoid arthritis. 7th
International TNF Congress, Hyannis, Mass. May 1998.
46. Edwards CK, Garrison, A., Reznikov, L., Fantuzzi, G., Bendele A, Chlipala E,
Frazier J, Zhou, T., Mountz, J. Dinarello, C. Induction of chronic synovitis and
generalized autoimmune disease in tumor necrosis factor- deficient mice
Page 19
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
treated with viable mycoplasma pulmonis. American College of
Rheumatology, San Diego. Nov. 1998.
47. Hamilton, M., Meyer, D., Desjardins, J., Tomkinson, B., Hooson, K., Emerson,
D., Bendele A, Dihel, L., McDermott, L., Leray, J., Brown, E., Moynihan, K.,
Chiang, S., Bendele, R. Pharamcokinetics, Distribution and Toxicology of
NX211 (Liposomal Lutotecan) in mice and rats. Annual Meeting of the
American Society of Clinical Oncology, 1999.
48. Chlipala, L, Bendele A, Dinarello, C. and Edwards, CE III. Mycoplasma
pulmonis-induced Arthritis in TNF- Knockout Mice (ko) and TNF
ko/TgA86 Mice: Characterization of the Models and Evaluation of Various
Anti-arthritic Agents. American College of Rheumatology Annual Meeting,
Boston, 1999.
49. Bendele A, Chlipala E, Rich, B and Edwards, CK, III Combination Benefit of
Treatment with IL-1ra and PEG sTNF-RI in Animal models of Arthritis.
American College of Rheumatology Annual Meeting, platform presentation,
Boston, 1999.
50. Bendele,A, Dinarello C, Chlipala, E, Edwards, III, CKIII. Effects of PEG
sTNF-RI, IL-1ra or the Combination in TNF- Knockout Mice expressing a
Mutant Transgenic form of Murine Transmembrane TNF. American Collage of
Rheumatology Annual Meeting, Poster, 2000.
51. Quintavalla J, Chambers M, Bendele A, O’Byrne E. Treatment of joint injury
by MMP inhibitors can delay exercise-dependent cartilage degeneration.
American College of Rheumatology Annual Meeting, Poster, 2002.
52. Schwendner S, Allameni K, Bendele A, Bucalo L, Sneedharan S. Antiarthritic efficacy of oral gallium maltolate in acute and chronic models of
rheumatoid arthritis. Experimental Biology Meeting, San Diego, CA, Poster
2005.
53. Pheneger J, Wallace E, Yeh T, Bendele A, Lee P. Characterization of a
potent MEK inhibitor in in vivo models of inflammatory disease. American7th
World Congress on inflammation, Australia, Poster, 2005.
54. Pheneger J, Munson M, Brown S, Gross S, Bendele A, Lee Patrice.
Characterization of a potent inhibitor of p38 kinase in in vivo models of
inflammatory disease. American College of Rheumatology Annual Meeting,
San Diego, CA, Poster, 2005.
55. Lee P, Pheneger J, Brown S, Gross S, Bendele A, Munson M.
Characterization of a potent inhibitor of p38 in in vitro and in vivo models of
inflammatory disease. Inflammatory research Society Meeting. Poster, 2005.
56. Connor J, LePage C, Bendele A, Maul D, Kumar S. Effects of an orally
administered cathepsin K inhibitor (SB-553484) on the beagle dog medial
meniscectomy model of osteoarthritis. Annual Meeting Osteoarthritis
Research Society International, Poster, 2005.
Page 20
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
57. Connor J, LePage C. Bendele A, Maul D, Kumar S. Protective effects of a
cathepsin K inhibitor (SB-553484) in a dog model of experimental
osteoarthritis. Orthopedic Research Society Meeting, Poster, 2006.
58. Slack J, Castner B, Jacobson E, Gates A, Tocker J, Alcorn D, Winters D,
Hecht R, Bendele A, Black RA. Injected TIMP-3 protects cartilage in a rat
meniscal tear model of osteoarthritis. Gordon Research Conference: Matrix
Metalloproteinases. Lucca, Italy. June 3-8, 2007.
59. Connor JR, LePage C, Swift BA, Vasko-Moser J, Bendele AM, Maul D,
Kumar S. Protective Effects of a Cathepsin Inhibitor in a Canine Model of
Experimental Osteoarthritis. Consensus Conference on Pre-Clinical Models of
OA hosted by the Canadian Arthritis Network. Montreal, Canada. May 1819, 2006
60. Pheneger J, Wallace E, Yang HW, Seo J, Lyssikatos J, Koch K, Bendele A
and Lee P. Effects of a Potent MEK Inhibitor on Two in vivo Models of
Contact Hypersensitivity. European Society of Dermatological Research
meeting. European Society for Dermatological Research. September 9,
2006.
61. Pheneger J, Wallace E, Marlow A, Hurley B, Lyssikatos J, Bendele A and
Lee P. Characterization of ARRY-438162, a Potent MEK Inhibitor in
Combination with Methotrexate or Ibuprofen in in vivo Models of Arthritis.
American College of Rheumatology. November 13, 2006.
62. Glasson SS, Levin J, Bendele AM, Rivéra-Bermúdez MA, Wang Q, Blanchet
TJ, Hopkins B, Peluso D, Morris EA. Selective MMP-13 Inhibitors are Not
Disease-Modifying in the Rat Meniscal Tear Model of Osteoarthritis. 53 rd
Annual Meeting of the Orthopaedic Research Society. San Diego CA.
February 11-14, 2007
63. Baragi VM, Bao B, Becher G, Bendele A, Bluhm H, Boer J, Deng H, Dodd R,
Essers M, Feuerstein T, Frickel F, Gallagher B, Gege C, Hochguertel M,
Hofmann M, Jaworski A, Kheil H, Kiely A, Korniski B, Kroth H, Nix D, Nolte B,
Piecha D, Powers T, Richter F, Schneider M, Steeneck C, Sucholeiki I,
Taveras A, Tejada J, Timmermann A, Van Veldhuizen J, Weik J, Wu E, Xia B.
New Class of Potent, Matrix Metalloproteinase-13 Specific Inhibitors For
Potential Treatment of Osteoarthritis. 53rd Annual Meeting of the Orthopaedic
Research Society. San Diego CA. February 11-14, 2007
64. Connor JR, LePage C, Swift BA, Yamashita DS, Bendele AM, Maul D,
Kumar S. Protective effects of a cathepsin K inhibitor, SB-553484, in the
canine medial meniscectomy model of osteoarthritis. 53rd Annual Meeting of
the Orthopaedic Research Society. San Diego CA. February 11-14, 2007
65. Ladel CH, Ellsworth JL, Bendele A.M. et al. Therapeutic Efficacy of
Fibroblast Growth Factor-18 in a Rat Model of Established Osteoarthritis.
OARSI World Congress on OA. Ft Lauderdale FL, Dec 8, 2007.
66. Flannery CR, Zollner R, Corcoran C, Jones ARC, Root A, Rivera-Bermudez
M, Blanchet T, Gleghorn JP, Bonassar LJ, Bendele AM, Morris EA, Glasson
SS. Lubricin supplementation prevents osteoarthritis progression in a rat
Page 21
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
surgical model. 54th Annual Meeting of the Orthopaedic Research Society.
San Francisco CA. March 5, 2008.
67. Sunyer T, Settle S, Vickery L, Nemirovsky O, Bendele A, Messing D,
Schnute M, Hellio MP, et al. Translational pharmacology strategy to evaluate
MMP-13 inhibitors for the treatment of OA; use of biomarkers. 2008 World
Congress on Osteoarthritis. Rome, Italy. September 2008.
68. Ladel CH, Gimona A, Vom Baur E, Ellsworth JL, Bendele AM. Recombinant
Human Fibroblast Growth Factor 18 as Therapy for Osteoarthritis: A Dog
Meniscectomy Model Study. 2008 World Congress on Osteoarthritis. Rome,
Italy. September 2008.
69. Flannery CR, Zollner R, Bendele AM, et al. Lubricin Supplementation
Prevents Osteoarthritis Progression in a Rat Surgical model. 2008 World
Congress on Osteoarthritis. Rome, Italy. September 2008.
70. Sunyer T, Settle S, Bendele AM, et al. Translational Pharmacology Strategy
to Evaluate MMP-13 Inhibitors for the Treatment of OA; Use of Biomarkers.
2008 World Congress on Osteoarthritis. Rome, Italy. September 2008.
71. Chambers MG, Oskins JL, Bendele AM, et al. CP-669685, a broad spectrum
MMP inhibitor with aggrecanase activity, inhibits both pain and joint
destruction in the meniscal tera model of osteoarthritis. 2008 World Congress
on Osteoarthritis. Rome, Italy. September 2008.
72. Dryer-Minnerly R, Stojanovic-Susulic V, Bendele A. Absence Of Leptin
Signaling Protects Obese Mice From Osteoarthritis. NAASO Meeting.
Phoenix AZ. October 4, 2008.
73. Scully M, Dryer-Minnerly R, Bendele A, et al. Progression of Osteoarthritis in
a Mouse Model of Obesity. OARSI Meeting. Montreal, Canada. September
12, 2009.
74. Black R, Gabel C, Lively S, Bendele A, et al. MMP-13 inhibitors reduce
nociception in a rat model of osteoarthritis. OARSI 2010 World Congress on
Osteoarthritis. Brussels, Belgium. September 23-26, 2010.
75. Levine Y, Maltys M, Black K, Caravaca A, Bendele A, Zitnik R.
Neurostimulation of the cholinergic anti-inflammatory pathway (NCAP)
ameliorates CIA in rats. EULAR Congress 2010. Rome, Italy, June 16-19
2010.
76. Castillo V, Bendele A, Li K, et al. Effects of oral administration of Hyal-Joint
in 17 day rat developing type II collagen arthritis. OARSI 2010 World
Congress on Osteoarthritis. Brussels, Belgium. September 23-26, 2010.
77. Shah V, Lieu Y, Bendele A, et al. Intra-tendon delivered recombinant human
platelet-derived growth factor-BB (rhPDGF-BB) enhances Achilles tendon
repair in a rat tendinopathy model. 2011 ORS Annual Meeting. Long Beach,
CA. January 13-16, 2011.
Page 22
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
78. Wathier M, Bansal PN, Entezari V, Bendele A, et al. Chondroprotection
using a novel synthetic viscosupplement in a rat OA model. 2011 ORS
Annual Meeting. Long Beach, CA. January 13-16, 2011.
79. Zhang K, Liu J, Deng J, Chang L, Shau J, Lu J, Bendele A, Fu Y, Duan J.
Modeling human rheumatoid arthritis in NHP: type II collagen induced arthritis
in cynomolgus macaques. 10th World Congress on Inflammation. Paris,
France. June 25-29, 2011.
80. Song, L, Bendele A, Coyle S, Zhang R, Davisson T. Correlation of pain and
structural damages in rat MIA model. OARSI 2011 World Congress on
Osteoarthritis. San Diego, CA September 15-18 2011.
81. Lindstrom E, Vrang L, Bendele A, et al. Effect of the selective cathepsin K
inhibitor, MIV-711, on markers of cartilage degradation and on gross and
histopathology scores in dogs subjected to partial medial meniscectomy, an
experimental model of osteoarthritis. OARSI 2011 World Congress on
Osteoarthritis. San Diego, CA September 15-18 2011.
82. Dines J, Shah VR, Bendele AM, Kestler H, et al. Recombinant Human
Platelet-Derived Growth Factor-BB (rhPDGF-BB) in a Rat Tendinopathy
Model. AAOS Annual Meeting. San Francisco, CA, February 7-11, 2012.
83. Song L, Bendele A, Coyle C, Zhang R, Davisson T. Effect of Intraarticular
injection of stem cells on joint pain and structural changes associated with
monoiodoacetate injection in rats. International Cartilage Repair Society
2012. Montreal, Canada, May 12-15, 2012
84. Wang S, Bendele A, Moore E. The chondroprotective effect of FGF9 in an
experimental model of osteoarthritis. OARSI 2012 World Congress on
Osteoarthritis. Barcelona, Spain, April 26-29, 2012.
85. Kumar A, Bendele A, Bodick N. Sustained efficacy of intra-articular FX006
in a rat model of osteoarthritis. OARSI 2012 World Congress on
Osteoarthritis. Barcelona, Spain, April 26-29, 2012.
86. Glasson S, Bendele A, Larkins N. APPA provides disease modification in
preclinical osteoarthritis. OARSI 2012 World Congress on Osteoarthritis.
Barcelona, Spain, April 26-29, 2012.
87. Ardizzone M, Kaufmann W, Steidler S, Marozin C, Bendele A. A proposal for
alternative trimming and inclusion procedure of the knee joint of rodents in
toxicity studies. 10th European Congres of Toxicologic Pathology. Stresa,
Italy, September 11-14, 2012.
88. Dines JS, Shah V, Solchaga LA, Bendele A, et al. Platelet-Derived Growth
Factor-BB, Platelet-Rich Plasma, Corticosteroids in a Tendinopathy Model.
AAOS Annual Meeting 2013. Chicago, IL, March 19-23, 2013.
89. Long P, Ernst H, Schelling S, Healy L, High W, Vahle J, Rinke M, Boyce R,
Boyle M, Bolon B, Fossey S, Bendele A, et al. International Harmonization of
Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice
Page 23
Alison M. Bendele, D.V.M., Ph. D.
_____________________________________________________________
(INHAND): Proposed Joint and Tooth Nomenclature. Society of Toxicologic
Pathology Annual Meeting 2013. Portland, OR, June 16-20, 2013.
90. Healy L, High W, Vahle J, Rinke M, Ernst H, Boyce R, Schelling S, Long P,
Boyle M, Bolon B, Fossey S, Bendele A, et al. International Harmonization of
Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice
(INHAND): Proposed Bone Nomenclature. Society of Toxicologic Pathology
Annual Meeting 2013. Portland, OR, June 16-20, 2013.
91. Kyostio-Moore S, Berthelette P, Piraino S, Moran N, Serriello J, Nambiar B,
Sookdeo C, Bendele A, Bangari D, Ewing P, et al. rAAV vector development
for local treatment of osteoarthritis. American Society of Gene & Cell Therapy
17th Annual Meeting. Washington, DC, May 21-24, 2014.
92. Vankayalapati H, Yerramreddy V, Bendele P, Bendele A, Anicattu Issac RJ,
ADluri RS, LoGrasso P, Kremer JM. Discovery of ARN-4079 – a Potent,
Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and
Interleukin-2 Inducivle T-Cell Kinase (ITK) for Rheumatoid Arthritis. American
College of Rheumatology Annual Meeting 2014. Boston, MA, Nov 14-19,
2014.
93. Decker D, Higgins P, Bendele A, Young D, Becker P. ACTH Gel (H.P.
Acthar Gel) Attenuates Established Collagen-Induced Arthritis When Used
Alone or as Adjuvant Therapy with Etanercept (Enbrel). Immunology 2015.
New Orleans, LA, May 8-12 2015.
94. Stevenson NR, Lattimer JC, Selting KA, Gonzales GR, Doerr CA, Bendele A,
Simon J, Srivastava SC. Homogeneous Sn-117m Colloid – A Novel
Radiosynovectomy Agent. 10th International Conference on
Radiopharmaceutical Therapy. Innsbruck, Austria, May 3-8, 2015.
Page 24